Overview: ARSA (MLD) TestIntroduction: The ARSA (MLD) Test measures arylsulfatase A enzyme activity to diagnose Metachromatic Leukodystrophy (MLD), a genetic disorder causing neurological decline, weakness, or vision loss, helping confirm this condition. Affecting 1 in 40,000 people annually, MLD poses diagnostic challenges due to its progressive nature. Following 2023 Leukodystrophy Alliance guidelines, it uses enzymatic assay for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, genetic counseling, and improving outcomes in neurology.
Other Names: Arylsulfatase A Test, MLD Enzyme Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Enzyme testing for MLD began in the 1960s with research by Kolodny, who identified ARSA deficiency. Enzymatic assay advancements in the 2000s by companies like PerkinElmer improved detection, surpassing earlier colorimetric methods.
Purpose: Measures ARSA activity to diagnose MLD, guides supportive therapy, and evaluates patients with neurological decline or weakness, aiming to manage symptoms and provide genetic counseling.
Test Parameters: Arylsulfatase A activity
Pretest Condition: No special preparation required. Collect whole blood or fibroblasts. Report history of neurological symptoms.
Specimen: Whole Blood (EDTA, 3-5 mL), Fibroblasts (sterile culture, ~1 cma³); 5 mL whole blood in Na Heparin tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document neurological decline or weakness. Include current medications or family history of leukodystrophy.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., disability), and sample collection risks.
Procedural Considerations: Uses enzymatic assay to measure ARSA activity, requiring labs with spectrophotometers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Low ARSA confirms MLD, guiding supportive care. Early diagnosis might slow progression, while untreated cases lead to death. Normal levels may require MRI or genetic tests.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: MRI, nerve conduction study, or genetic panel to confirm diagnosis.
Test Limitations: Specific to MLD; correlation with symptoms needed. False negatives possible with sample issues.
References: Leukodystrophy Alliance Guidelines, 2023; Journal of Neurology, Kolodny EH, 2022.
